(NASDAQ: RZLT) Rezolute's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.05%.
Rezolute's earnings in 2026 is -$81,485,000.On average, 12 Wall Street analysts forecast RZLT's earnings for 2026 to be -$70,129,705, with the lowest RZLT earnings forecast at -$80,211,512, and the highest RZLT earnings forecast at -$67,741,655. On average, 12 Wall Street analysts forecast RZLT's earnings for 2027 to be -$64,920,290, with the lowest RZLT earnings forecast at -$82,098,841, and the highest RZLT earnings forecast at -$45,498,126.
In 2028, RZLT is forecast to generate -$39,431,710 in earnings, with the lowest earnings forecast at -$58,507,220 and the highest earnings forecast at -$18,199,251.